DENVER — About one-third of patients with diabetic macular edema discontinue anti-VEGF therapy in any given year and do not resume it, according to data from the IRIS Registry.
A retrospective analysis evaluated real-world anti-VEGF use among patients with DME.
“[The IRIS Registry] is one of the largest electronic health records in the world,” David Tabano, PhD, told Healio/OSN at the Association for Research in Vision and Ophthalmology meeting. “This is a fantastic representation of the patient population in the United States that are afflicted with DME and what their